Anti-Drug Antibodies in the Biological Therapy of Autoimmune Rheumatic Diseases

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 May 13

PMID 37176711

Authors

Oscar Pizano-Martinez

Edgar Mendieta-Condado

Monica Vazquez-Del Mercado

Erika Aurora Martinez-Garcia

Efrain Chavarria-Avila

Daniel Ortuno-Sahagun

Ana Laura Marquez-Aguirre

Affiliations

Soon will be listed here.

Abstract

Autoimmune rheumatic diseases are a cluster of heterogeneous disorders that share some clinical symptoms such as pain, tissue damage, immune deregulation, and the presence of inflammatory mediators. Biologic disease-modifying antirheumatic drugs are some of the most effective treatments for rheumatic diseases. However, their molecular and pharmacological complexity makes them potentially immunogenic and capable of inducing the development of anti-drug antibodies. TNF inhibitors appear to be the main contributors to immunogenicity because they are widely used, especially in rheumatoid arthritis. Immunogenicity response on these treatments is crucial since the appearance of ADAs has consequences in terms of safety and efficacy. Therefore, this review proposes an overview of the immunogenicity of biological agents used in autoimmune rheumatic diseases highlighting the prevalence of anti-drug antibodies.

Citing Articles

What are clinically significant anti-drug antibodies and why is it important to identify them.

Swanson S Front Immunol. 2024; 15:1401178.

PMID: 39737166 PMC: 11682980. DOI: 10.3389/fimmu.2024.1401178.

ANGPTL4 mediated mesothelial-mesenchymal transition in pulmonary fibrosis: a potential therapeutic target.

Xia Y, Zhou F, Hui H, Dai L, Ouyang S J Transl Med. 2024; 22(1):1114.

PMID: 39707362 PMC: 11662423. DOI: 10.1186/s12967-024-05869-2.

Advances in immunotoxin engineering: precision therapeutic strategies in modern oncology.

Oghalaie A, Hosseini M, Hosseininejad-Chafi M, Eftekhari Z, Behdani M, Kazemi-Lomedasht F Med Oncol. 2024; 41(10):239.

PMID: 39230639 DOI: 10.1007/s12032-024-02478-3.

Impact of initiation of targeted therapy on the use of psoriatic arthritis-related treatments and healthcare consumption: a cohort study of 9793 patients from the French health insurance database (SNDS).

Pina Vegas L, Iggui S, Sbidian E, Claudepierre P RMD Open. 2024; 10(3).

PMID: 39117446 PMC: 11409354. DOI: 10.1136/rmdopen-2024-004631.

Emicizumab as first-line therapy in acquired hemophilia A.

Iarossi M, Hermans C Res Pract Thromb Haemost. 2024; 8(4):102438.

PMID: 38953052 PMC: 11215093. DOI: 10.1016/j.rpth.2024.102438.

References

Harding F, Stickler M, Razo J, DuBridge R . The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010; 2(3):256-65. PMC: 2881252. DOI: 10.4161/mabs.2.3.11641. View

Spindeldreher S, Maillere B, Correia E, Tenon M, Karle A, Jarvis P . Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab. Dermatol Ther (Heidelb). 2018; 8(1):57-68. PMC: 5825325. DOI: 10.1007/s13555-018-0220-y. View

Jani M, Chinoy H, Warren R, Griffiths C, Plant D, Fu B . Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. Arthritis Rheumatol. 2015; 67(8):2011-9. PMC: 4843946. DOI: 10.1002/art.39169. View

Pombo-Suarez M, Gomez-Reino J . Abatacept for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2019; 15(4):319-326. DOI: 10.1080/1744666X.2019.1579642. View

Moutsopoulos H . Autoimmune rheumatic diseases: One or many diseases?. J Transl Autoimmun. 2022; 4:100129. PMC: 8716565. DOI: 10.1016/j.jtauto.2021.100129. View

Krieckaert C, van Tubergen A, Gehin J, Hernandez-Breijo B, Le Meledo G, Balsa A . EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2022; 82(1):65-73. DOI: 10.1136/annrheumdis-2022-222155. View

Lichtenstein L, Ron Y, Kivity S, Ben-Horin S, Israeli E, Fraser G . Infliximab-Related Infusion Reactions: Systematic Review. J Crohns Colitis. 2015; 9(9):806-15. PMC: 4558633. DOI: 10.1093/ecco-jcc/jjv096. View

Siljehult F, Arlestig L, Eriksson C, Rantapaa-Dahlqvist S . Concentrations of infliximab and anti-drug antibodies in relation to clinical response in patients with rheumatoid arthritis. Scand J Rheumatol. 2018; 47(5):345-350. DOI: 10.1080/03009742.2018.1433232. View

Jani M, Barton A, Warren R, Griffiths C, Chinoy H . The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford). 2013; 53(2):213-22. PMC: 3894670. DOI: 10.1093/rheumatology/ket260. View

10.

Mariette X, Forger F, Abraham B, Flynn A, Molto A, Flipo R . Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2017; 77(2):228-233. PMC: 5867410. DOI: 10.1136/annrheumdis-2017-212196. View

11.

Giacomelli R, Afeltra A, Alunno A, Bartoloni-Bocci E, Berardicurti O, Bombardieri M . Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. Autoimmun Rev. 2018; 18(1):93-106. DOI: 10.1016/j.autrev.2018.08.003. View

12.

Burmester G, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D . A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe.... Ann Rheum Dis. 2013; 73(1):69-74. PMC: 3888614. DOI: 10.1136/annrheumdis-2013-203523. View

13.

Benucci M, Grossi V, Manfredi M, Damiani A, Infantino M, Moscato P . Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity. Ann Lab Med. 2019; 40(2):101-113. PMC: 6822010. DOI: 10.3343/alm.2020.40.2.101. View

14.

Karle A, Spindeldreher S, Kolbinger F . Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity. MAbs. 2016; 8(3):536-50. PMC: 4966846. DOI: 10.1080/19420862.2015.1136761. View

15.

Arstikyte I, Kapleryte G, Butrimiene I, Venalis A . Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF α Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients. Biomed Res Int. 2015; 2015:604872. PMC: 4427010. DOI: 10.1155/2015/604872. View

16.

Tavakolpour S, Alesaeidi S, Darvishi M, Ghasemiadl M, Darabi-Monadi S, Akhlaghdoust M . A comprehensive review of rituximab therapy in rheumatoid arthritis patients. Clin Rheumatol. 2019; 38(11):2977-2994. DOI: 10.1007/s10067-019-04699-8. View

17.

Nash P, Nayiager S, Genovese M, Kivitz A, Oelke K, Ludivico C . Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study. Arthritis Care Res (Hoboken). 2012; 65(5):718-28. DOI: 10.1002/acr.21876. View

18.

Buer J . A history of the term "DMARD". Inflammopharmacology. 2015; 23(4):163-71. PMC: 4508364. DOI: 10.1007/s10787-015-0232-5. View

19.

Harrison J, Weber S, Jakob R, Chute C . ICD-11: an international classification of diseases for the twenty-first century. BMC Med Inform Decis Mak. 2021; 21(Suppl 6):206. PMC: 8577172. DOI: 10.1186/s12911-021-01534-6. View

20.

Levy R, Gonzalez-Rivera T, Khamashta M, Fox N, Jones-Leone A, Rubin B . 10 Years of belimumab experience: What have we learnt?. Lupus. 2021; 30(11):1705-1721. PMC: 8564244. DOI: 10.1177/09612033211028653. View